# Chiesi Group account plan

> Chiesi Group is a family-owned Parma pharmaceutical group in respiratory, rare diseases and specialty care, with FY2025 revenues of €3,625M.

## At a glance

Chiesi Group is a family-owned, research-focused pharmaceutical group founded in 1935 and headquartered in Parma, Italy, controlled through Valline S.r.l. It develops and sells medicines in three business areas: Air (respiratory), Rare (rare and ultra-rare diseases) and Care (neonatology, transplant, cardiovascular and consumer healthcare), through 31 affiliates, 4 production plants and 7 R&D centres. FY2025 consolidated revenues were €3,625M (+8.2% at constant exchange rates), with EBITDA of €931M (25.7% of revenues) and record R&D investment of €885M. The group had 7,934 employees at end-2025 and is a Benefit Corporation and certified B Corp; Jean-Marc Bellemin is CFO and Interim Group CEO.

## Business units

- **Air (respiratory health)** (about 52% of FY2025 revenues (€1,886M)): Inhaled treatments for asthma, COPD, idiopathic pulmonary fibrosis, bronchiectasis and pulmonary arterial hypertension, with Foster, Trimbow and Clenil as main products. Revenue grew 3.9% at CER in 2025, driven by 15.8% growth of the triple inhaled therapy against generic competition on legacy products; in H1 2026 respiratory was broadly stable (-0.8% @CER). The Carbon Minimal Inhaler programme moves pMDIs to a low-GWP propellant.
- **Care (specialty care)** (about 25% of FY2025 revenues (€904M)): Products for neonatal respiratory distress, apnea of premature newborns, solid organ transplant, acute and cardiovascular diseases and consumer healthcare, including Curosurf, Kengreal, Envarsus, Cleviprex and Peyona. Revenue grew 13.3% at CER in 2025 and neonatology and specialty care grew 6.5% @CER in H1 2026.
- **Rare (Chiesi Global Rare Diseases)** (about 23% of FY2025 revenues (€835M)): Treatments for inborn defects of metabolism, rare haematologic and immunologic diseases, endo-metabolic disorders and dermatology, including Myalept, Revcovi, Elfabrio and Ferriprox. Based in Boston and expanded by the Amryt Pharma acquisition, it was the main growth engine in H1 2026 (+9.9% @CER) and added KalVista Pharmaceuticals' oral HAE treatment.

## Strategic priorities

- **€6 billion of sales by 2030**: Chiesi aims to reach €6 billion of sales by 2030, with around 10-15% of the goal from acquisitions in respiratory, specialty pharma and rare diseases.
- **Grow rare diseases and the U.S.**: Rare diseases and the United States drive growth: the U.S. grew 28.9% at CER in 2025 and 9.6% @CER in H1 2026.
- **Carbon Minimal Inhaler rollout**: Move six pMDI formulations to the low-GWP, non-PFAS propellant HFA 152a, cutting product footprint by up to 90%, with a Bespak partnership to deliver CMIs at scale.
- **Climate targets**: SBTi targets of a 90% cut in Scope 1 and 2 emissions by 2030 and a 90% cut in key Scope 3 categories by 2035, both against 2019.
- **Mid-single-digit growth in 2026**: The 2026 outlook is mid-single-digit revenue growth, with late-stage respiratory programmes and low-GWP propellant pMDI launches.

## Latest results

In H1 2026 (six months to 30 June) revenues were €1.89 billion, up 3.6% at constant exchange rates excluding the KalVista acquisition, slower than the 8.2% growth of FY2025. Rare diseases grew 9.9% @CER, neonatology and specialty care 6.5% and respiratory was broadly stable at -0.8%. By region the United States grew 9.6% @CER, Europe 0.9% and remaining geographies 5.5%. The EBITDA margin was 29.4% and R&D investment €426 million, about 22.5% of revenues.

## Investments and deals

- **KalVista Pharmaceuticals acquisition**: Completed in H1 2026, adding an oral on-demand treatment for hereditary angioedema and expanding the U.S. presence.
- **Nerviano site**: Industrial site near Milan acquired in March 2025 and being redeveloped for sterile biologics and carbon-minimal inhalers.
- **Biotech Center of Excellence in Parma**: A €400M investment inaugurated in 2024, integrating the full biologics production process.
- **Rare disease partnerships**: Three 2025 partnerships with Key2Brain, Arbor Biotechnologies and Aliada Therapeutics on brain-penetrating enzyme therapies and gene editing.
- **Record R&D**: R&D investment of €885M in FY2025, 24.4% of revenues.

## Challenges and risks

- **Slowing growth and flat Europe**: H1 2026 growth slowed to 3.6% @CER, with Europe at +0.9% and EU Top5 markets broadly stable in 2025.
- **Generics on legacy respiratory products**: Continued generic competition on legacy respiratory products is offset only by growth of the triple inhaled therapy.
- **Inhaler propellant regulation**: Regulatory pressure on high-GWP inhaler propellants and a market shift to dry powder and soft mist inhalers are the key climate risk.
- **Supply chain dependence**: Dependence on direct suppliers and external manufacturers can cause shortages, delays and quality issues affecting critical therapies.
- **CEO transition and U.S. tariffs**: CEO Giuseppe Accogli left on 15 May 2026 and a permanent successor is being sought; U.S. tariffs may eventually require U.S. manufacturing.

## What leadership says

> "the acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S." — Jean Marc Bellemin, CFO and Interim CEO, H1 2026 results release, 9 September 2026

> "We are looking in respiratory, in specialty pharma and in rare diseases, not only in Italy, but also globally." — Giuseppe Accogli, Group CEO (until May 2026), Reuters interview, 5 June 2025

> "reflect the resilience of our strategy and the strength of our global footprint" — Jean Marc Bellemin, CFO and Interim CEO, H1 2026 results release, 9 September 2026


## Where a supplier can help

- **Inhaler manufacturing and propellant transition**: The Carbon Minimal Inhaler rollout and Nerviano redevelopment need device, filling-line and engineering suppliers.
- **U.S. rare disease commercial build-out**: U.S. growth and the KalVista integration call for patient support, market access and CRM providers in rare diseases.
- **Supply chain resilience**: Supply chain dependence on external manufacturers creates demand for supplier risk monitoring, CMOs and inventory planning tools.
- **Emissions reduction across the value chain**: The 2030 and 2035 SBTi targets push Chiesi to work with vendors on CO2 reduction, opening doors for energy, logistics and carbon accounting suppliers.
- **Clinical development support**: Record R&D and late-stage respiratory programmes create demand for CROs and clinical data services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Chiesi Group Sustainability Report 2025 (group annual report)](https://www.chiesi.com/content/dam/chiesi-corporate/global/en/archive/document-archive/2026/sustainability_report_2025.pdf)

Annual report

- Chiesi Group is a family-owned, Parma-headquartered research-focused pharmaceutical group (founded 1935) organised in three business areas, Air (respiratory), Rare (rare and ultra-rare diseases) and Care (neonatology, transplant, cardiovascular, consumer healthcare); 31 affiliates, 4 production plants and 7 R&D centres; parent company Valline S.r.l.
- FY2025 consolidated revenues €3,625M (2024: €3,413M), +8.2% at constant exchange rates; EBITDA €931M, 25.7% of revenues (2024: €1,004M, 29.4%).
- By business area: Air €1,886M (+3.9% @CER), Care €904M (+13.3%), Rare €835M (+13.0%); Trimbow, the fixed triple combination for asthma and COPD, "contributed considerably" to 2025 growth.
- Record R&D investment of €885M, 24.4% of revenues (2024: €829M, 24.3%); 6,324 patents in the portfolio and 36 first filings at the EPO; 1st among Italian pharmaceutical companies in the EU Industrial R&D Investment Scoreboard.
- Workforce of 8,081 (7,732 internal employees plus 349 external collaborators): Italy 32.7%, rest of Europe 34.4%, North America 25.1%, rest of world 7.8%.
- Economic value generated €3,662M, of which €3,012M (about 82%) distributed (suppliers €1,850M, employees €874M) and €650M retained to self-finance innovation.
- Industrial investments: €400M Biotech Center of Excellence in Parma (opened 2024); new Nerviano site (near Milan) acquired in March 2025 for inhalers and biologics.
- Carbon Minimal Inhaler programme: six pMDI formulations moving to the low-GWP, non-PFAS propellant HFA 152a, cutting product footprint by up to 90%; phase III safety study for the fixed triple completed and the beclomethasone CMI pMDI submitted to the UK MHRA at end-2025. SBTi targets: -90% Scope 1-2 by 2030 and -90% for key Scope 3 categories by 2035 vs 2019.
- Governance: Benefit Corporation (Italy, US, France, Colombia), third B Corp certification in 2025 with a score of 117.5; three independent non-executive directors (Roch Doliveux, Paolo Pucci, Daphne Quimi) joined the Board in January 2025, which set up three Board committees.
- Key risks named: supply chain and own-plant disruptions affecting critical therapies, REACH / substances-of-concern regulation, regulatory pressure on high-GWP inhaler propellants and the market shift to dry-powder and soft-mist inhalers, cybersecurity.

### [Chiesi Group delivers solid H1 2026 performance (H1 2026 results release)](https://www.chiesi.com/content/dam/chiesi-corporate/global/media-hub/press-release/2026/chiesi-group-delivers-solid-h1-2026-performance-combining-growth-continued-investment-positive-economic-impact/chiesi-group-delivers-solid-h1-2026-performance-combining-growth-continued-investment-in-innovation-and-positive-economic-impact-across-communities.pdf)

Interim report · 2026-09-09

- H1 2026 revenues €1.89 billion, +3.6% at CER vs H1 2025, excluding the KalVista acquisition.
- Rare diseases grew +€45m (+9.9% @CER); neonatology and specialty care +6.5% @CER; respiratory broadly stable (-0.8% @CER) with strong growth of the inhaled triple therapy portfolio.
- By region: United States +9.6% @CER, Europe +0.9%, remaining geographies +5.5%.
- EBITDA margin 29.4%; solid operating cash generation funds pipeline, manufacturing and acquisitions.
- R&D investment €426 million, about 22.5% of revenues, including the Carbon Minimal Inhaler platform and a strategic partnership with Bespak to deliver CMIs at scale.
- Completed the acquisition of KalVista Pharmaceuticals (US), adding an oral on-demand treatment for hereditary angioedema (HAE) to the rare disease platform.
- PwC Italy economic footprint study (2025): about €6 billion of GDP, 56,488 jobs and nearly €2 billion in taxes worldwide; Europe €4.1 billion GDP and 78% of global R&D investment.
- Jean Marc Bellemin is CFO and Interim CEO.

### [Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition](https://www.chiesi.com/content/dam/chiesi-corporate/global/media-hub/press-release/2026/chiesi-reports-strong-fy2025-financial-sustainability-results/doc_582.pdf)

Interim report · 2026-04-23

- FY2025 consolidated revenues €3.625 billion, +8.2% at CER; EBITDA €931 million (25.7%).
- Positive net financial position of €729 million (cash minus financial liabilities including leasing), up €194 million vs 2024.
- Rare sales €906 million (+22.3% at CER), representing 50% of total group growth; Air €1.886 billion (+3.9%) with the triple inhaled therapy up 15.8%; Care €904 million (+13.3%).
- US fastest-growing region (+28.9% at CER); EU midsize countries +9.8%; EU Top5 broadly stable (-0.6%).
- Record R&D investment of €885 million (24.4% of revenues); three rare disease partnerships in 2025 (Key2Brain, Arbor Biotechnologies, Aliada Therapeutics).
- CEO Giuseppe Accogli leaves on 15 May 2026; Group CFO Jean-Marc Bellemin named Interim Group CEO while a search is underway.
- 2026 outlook: mid-single-digit revenue growth; late-stage respiratory programmes and low-GWP propellant pMDI launches.
- Scope 1 and 2 emissions down 56% vs 2019; EcoVadis Platinum (88/100); 7,934 employees after 392 new roles.

### [Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030 (Reuters interview)](https://d2649.cms.socastsrm.com/2025/06/05/italys-chiesi-group-plans-acquisitions-to-boost-sales-to-6-billion-euros-by-2030/)

Executive talk · Giuseppe Accogli, Group CEO (until May 2026) · 2025-06-05

- Chiesi aims to reach €6 billion of sales by 2030 (doubling) and to significantly increase the number of patients treated from around 10 million.
- Acquisitions are part of the plan: around 10-15% of the sales goal should come from inorganic opportunities being scouted.
- Target areas for M&A: respiratory, specialty pharma and rare diseases, in Italy and globally; "no rush".
- Chiesi has no debt and earns around €1 billion of EBITDA a year, giving "firepower" to reach €5-6 billion of sales with its own resources.
- Declined to comment on any approach to listed Italian rival Recordati: "we always look at everything that is available".
- 2025 expected revenue growth of more than mid-single digit, after 13% growth in 2024 to €3.4 billion.
- US tariffs described as "still very confused"; a US manufacturing presence may eventually be needed to complement sites in France, Italy and Brazil, but nothing concrete is planned.

## Questions about Chiesi Group

### What does Chiesi Group do?

Chiesi is a family-owned pharmaceutical group from Parma that develops and sells medicines for respiratory health, rare diseases and specialty care such as neonatology and transplant.

### What is Chiesi's revenue?

FY2025 consolidated revenues were €3,625M, up 8.2% at constant exchange rates, with EBITDA of €931M. H1 2026 revenues were €1.89 billion.

### How many employees does Chiesi have?

Chiesi had 7,934 employees at the end of 2025, after creating 392 new roles.

### Who leads Chiesi Group?

Alessandro Chiesi is Chairperson. Jean-Marc Bellemin is Group CFO and Interim Group CEO since Giuseppe Accogli left on 15 May 2026.

### What is Chiesi's strategy?

Chiesi aims to reach €6 billion of sales by 2030 through growth in rare diseases, the U.S. and acquisitions, while moving its inhalers to a low-GWP propellant.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
